First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.

Kyriakos P.  Papadopoulos

Consulting or Advisory Role - ArQule (Inst); Bayer (Inst)

Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Formation Biologics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst); Syros Pharmaceuticals (Inst)

Nehal J.  Lakhani

No Relationships to Disclose

Melissa Lynne  Johnson

Consulting or Advisory Role - Araxes Pharma (Inst); Astellas Pharma (I); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Incyte (Inst); Loxo (Inst); Merck (Inst); Mersana (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Otsuka (I); Pfizer (Inst); Ribon Therapeutics (Inst); Sanofi (Inst)

Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BerGenBio (Inst); Birdie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Checkpoint Therapeutics (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Foundation Medicine (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Incyte (Inst); Janssen (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Neovia Oncology (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Stem CentRx (Inst); Syndax (Inst); Syndax (Inst); Tarveda Therapeutics (Inst)

Travel, Accommodations, Expenses - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; EMD Serono; Exelixis; Genentech; Incyte; Merck; Pfizer; Sysmex; Vapotherm

Haeseong  Park

Research Funding - Ambrx (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst); Taiho Pharmaceutical (Inst); Vertex (Inst); Vertex (Inst)

Travel, Accommodations, Expenses - Bayer

Ding  Wang

Consulting or Advisory Role - Merck

Travel, Accommodations, Expenses - Merck

Timothy A  Yap

Honoraria - AstraZeneca; Pfizer

Consulting or Advisory Role - Aduro Biotech; Almac Diagnostics; AstraZeneca; Atrin Pharmaceuticals; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; Cybrexa Therapeutics; EMD Serono; Ignyta; Janssen; Merck; Pfizer; Roche; Seagen; Tesaro; Vertex

Speakers' Bureau - AstraZeneca

Research Funding - AstraZeneca; Bayer; Constellation Pharmaceuticals; Jounce Therapeutics; Kyowa Hakko Kirin; Lilly; Pfizer; Seagen; Tesaro; Vertex

Patents, Royalties, Other Intellectual Property - MD Anderson Cancer Center holds the intellectual property rights to IACS-010759 and its designated use. (Inst)

Travel, Accommodations, Expenses - EMD Serono; Pfizer; Tesaro

Afshin  Dowlati

Consulting or Advisory Role - Abbvie/Stemcentrx; ARIAD

Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Lilly/ImClone (Inst); MedImmune (Inst); OncoMed (Inst)

Robert G.  Maki

Honoraria - Lilly; Springer; Wiley

Consulting or Advisory Role - AADi; American Board of Internal Medicine (ABIM); Arcus Ventures; Bayer; Deciphera; Foundation Medicine; Janssen Scientific Affairs; Karyopharm Therapeutics; Lilly/ImClone; SARC: Sarcoma Alliance for Research though Collaboration; TRACON Pharma

Research Funding - Abbvie (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); FORMA Therapeutics (Inst); Immunocore (Inst); Lilly (Inst); Pfizer (Inst); Presage Biosciences (Inst); Regeneron (Inst); TRACON Pharma (Inst); Xencor (Inst)

Patents, Royalties, Other Intellectual Property - Springer and Wiley: Books for contributions I have made to the published texts; Uptodate: I write and edit chapters for their online text book.

Travel, Accommodations, Expenses - Bayer; TRACON Pharma

Filipa  Lynce

Research Funding - AstraZeneca; Bristol-Myers Squibb; Calithera Biosciences (Inst); Chugai Pharma USA (Inst); Immunomedics (Inst); Inivata (Inst); Jounce Therapeutics; Pfizer; Regeneron (Inst); Tesaro (Inst)

Susanna Varkey  Ulahannan

Consulting or Advisory Role - Bayer; Exelixis

Research Funding - Abbvie (Inst); ArQule (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); G1 Therapeutics (Inst); Incyte (Inst); Klus Pharma (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Takeda (Inst)

Karen  Kelly

Honoraria - Merck

Consulting or Advisory Role - Abbvie; AstraZeneca; EMD Serono; Genentech/Roche; Janssen; Lilly; Merck; Pfizer; Regeneron

Research Funding - Abbvie (Inst); Celgene (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Lilly (Inst); Lycera (Inst); Regeneron (Inst); Transgene (Inst)

Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.

Travel, Accommodations, Expenses - Abbvie; AstraZeneca; EMD Serono; Genentech/Roche; Lilly; Merck; Regeneron

Tasha Nicholle  Sims

Employment - Regeneron

Stock and Other Ownership Interests  - Regeneron

Patents, Royalties, Other Intellectual Property - Named on patents (I)

Travel, Accommodations, Expenses - Regeneron

Amy-Lee  Bredlau

Employment - Regeneron

Stock and Other Ownership Interests  - Regeneron

Research Funding - Azevan Pharmaceuticals

Patents, Royalties, Other Intellectual Property - Advance Nano Delivery

Derrick  Bramble

Employment - Regeneron

Stock and Other Ownership Interests  - Regeneron

Travel, Accommodations, Expenses - Regeneron

Ana  Gonzalez Ortiz

Employment - Regeneron

Leadership - Pfizer (I)

Stock and Other Ownership Interests  - Regeneron

Honoraria - Agenus; Regeneron

Consulting or Advisory Role - Agenus (I); Pfizer (I); Vertex (I)

Patents, Royalties, Other Intellectual Property - Agenus; Agenus (I); Broad Institute; Broad Institute (I)

Travel, Accommodations, Expenses - Pfizer (I); Vertex (I)

Min  Zhu

Employment - Regeneron

Stock and Other Ownership Interests  - Regeneron

Huanyu  Chen

Employment - Novartis; Novartis (I); Regeneron; Regeneron (I)

Stock and Other Ownership Interests  - Regeneron

Maria  Karasarides

Employment - AstraZeneca/MedImmune; Regeneron

Stock and Other Ownership Interests  - AstraZeneca/MedImmune; Regeneron

Research Funding - AstraZeneca/MedImmune; Regeneron

Patents, Royalties, Other Intellectual Property - Declaration PCT Application No: PCT/US2017/025246: Combinations of an anti-BR-H1 antibody and a CXCR4 peptide antagonist for treating a solid tumor.; Declaration PCT Application No: PCT/US2017/058684: Combination of anti-VEGFR2 antibody and an anti-PD-L1 antibody for the treatment of cancer.

Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Regeneron

Glenn  Kroog

No Relationships to Disclose